RESUMEN
Bone morphogenetic protein-7 (BMP-7) counteracts pro-fibrotic effects of TGFß1 in cultured renal cells and protects from fibrosis in acute and chronic renal injury models. Using the unilateral ureteral obstruction (UUO) model of chronic renal fibrosis, we investigated the effect of exogenous-rhBMP-7 on pro-fibrotic signaling pathways mediated by TGFß1 and hypoxia. Mice undergoing UUO were treated with vehicle or rhBMP-7 (300µg/kg i.p.) every other day for eight days and kidneys analysed for markers of fibrosis and SMAD, MAPK, and PI3K signaling. In the kidney, collecting duct and tubular epithelial cells respond to BMP-7 via activation of SMAD1/5/8. Phosphorylation of SMAD1/5/8 was reduced in UUO kidneys from vehicle-treated animals yet maintained in UUO kidneys from BMP-7-treated animals, confirming renal bioactivity of exogenous rhBMP-7. BMP-7 inhibited Collagen Iα1 and Collagen IIIα1 gene expression and Collagen I protein accumulation, while increasing expression of Collagen IVα1 in UUO kidneys. Activation of SMAD2, SMAD3, ERK, p38 and PI3K/Akt signaling occurred during fibrogenesis and BMP-7 significantly attenuated SMAD3 and Akt signaling in vivo. Analysis of renal collecting duct (mIMCD) and tubular epithelial (HK-2) cells stimulated with TGFß1 or hypoxia (1% oxygen) to activate Akt provided further evidence that BMP-7 specifically inhibited PI3K/Akt signaling. PTEN is a negative regulator of PI3K and BMP-7 increased PTEN expression in vivo and in vitro. These data demonstrate an important mechanism by which BMP-7 orchestrates renal protection through Akt inhibition and highlights Akt inhibitors as anti-fibrotic therapeutics.
Asunto(s)
Proteína Morfogenética Ósea 7/metabolismo , Proteína Morfogenética Ósea 7/farmacología , Fibrosis/prevención & control , Fosfohidrolasa PTEN/metabolismo , Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores , Animales , Hipoxia de la Célula/fisiología , Línea Celular , Colágeno/metabolismo , Modelos Animales de Enfermedad , Fibrosis/enzimología , Fibrosis/patología , Enfermedades Renales/enzimología , Enfermedades Renales/patología , Enfermedades Renales/prevención & control , Túbulos Renales/efectos de los fármacos , Túbulos Renales/patología , Ratones , Fosfohidrolasa PTEN/biosíntesis , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal/efectos de los fármacos , Proteínas Smad/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo , Regulación hacia ArribaRESUMEN
We designed and synthesized a novel series of phenylamino- and phenoxy-substituted pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists. SAR studies indicated that electron-withdrawing substituents on the phenyl ring are important for potency and full efficacy. Compound 26 combined good potency with a promising pharmacokinetic profile in mice, and lowered the glucose excursion in mice in an oral glucose-tolerance test.
Asunto(s)
Descubrimiento de Drogas , Pirimidinas/química , Pirimidinas/farmacología , Receptores Acoplados a Proteínas G/agonistas , Animales , Humanos , Ratones , Pirazoles/síntesis química , Pirazoles/química , Pirazoles/farmacología , Pirimidinas/síntesis química , Relación Estructura-ActividadRESUMEN
Starting from screening hit, (4S,7R)-1,7,8,8-tetramethyl-2-phenyl-1,2,4,5,6,7-hexahydro-4,7-methano-indazol-3-one (7), we optimized the potency and pharmacokinetic properties. This led to the identification of compounds with good in vivo activity in a mouse pharmacodynamic model of inhibition of 11ßHSD1.
Asunto(s)
11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1/antagonistas & inhibidores , Alcanfor/química , Descubrimiento de Drogas , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Pirazolonas/síntesis química , Pirazolonas/farmacología , 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1/metabolismo , Animales , Activación Enzimática/efectos de los fármacos , Femenino , Hidrocortisona/sangre , Concentración 50 Inhibidora , Ratones , Estructura Molecular , RatasRESUMEN
Recombinant human serum albumin (HSA) conjugates of a 15-amino-acid truncated peptide YY (PYY) analogue were prepared using three heterobifunctional linkers [succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC), 6-maleimidohexanoic acid N-hydroxysuccinimide ester (MHS), and N-[γ-maleimidobutyryloxy]sulfosuccinimide ester (GMBS)] in 2 synthetic steps involving (1) reaction of succinimidyl ester on linker with ε-amine of Lys2 on the peptide and (2) reaction of maleimide on peptide linker with free thiol of Cysteine 34 (Cys34) on albumin. In-process controls using ESI LC-MS were used to follow reactions and identify reaction products. Proteolytic digests of the conjugate revealed that peptide conjugation occurs at Cys34 on HSA. Conjugates were assayed in cell-based assays to determine potency at the human Y2-receptor, and selectivity at the human Y1-, Y4-, and Y5-receptors using a calcium flux assay. All three conjugates assayed were selective agonists of the Y2-receptor, and displayed nanomolar potencies. MCC and MH conjugates were selected for acute PK/PD studies in DIO mice. Significant reduction in food intake was observed with the MH conjugate, which lasted for 24 h at the 10 mg (or 4 µmol)/kg dose. While the MCC conjugate exhibited greater potency in vitro, it was slightly less effective than the MH conjugate in vivo with respect to reduction in food intake. Both conjugates were significantly less active than the peptide coupled to a 30 kDa PEG. The observed T1/2 (8-9 h) for both conjugates was significantly lower than that observed for the PEGylated peptide (â¼25 h). These results suggest that, as compared with the unmodified and PEGylated peptide, the extended circulation half-life of albumin conjugates is mediated through uptake and recirculation by FcRn, and allometric scaling methods are necessary to account for interspecies variation in pharmacokinetic properties.
Asunto(s)
Péptido YY/metabolismo , Albúmina Sérica/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Ingestión de Alimentos/efectos de los fármacos , Semivida , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Modelos Moleculares , Datos de Secuencia Molecular , Peso Molecular , Péptido YY/química , Unión Proteica , Conformación Proteica , Albúmina Sérica/química , Albúmina Sérica/farmacología , Especificidad por SustratoRESUMEN
Benzimidazole and indane are the two key fragments in our potent and selective MCH-1 receptor (MCHR1) antagonists. To identify novel linkers connecting the two fragments, we investigated diamino-cycloalkane-derived analogs and discovered highly potent antagonists with cis-1,4-diaminocyclohexane as a unique spacer in this chemical class. Structural overlay suggested that cis-1-substituted-4-aminocyclohexane functions as a bioisostere of 4-substituted-piperidine and that the active conformation adopts a U-shaped orientation.
Asunto(s)
Ciclohexanos/química , Indanos/química , Receptores de la Hormona Hipofisaria/antagonistas & inhibidores , Animales , Bencimidazoles/química , Semivida , Indanos/metabolismo , Indanos/farmacocinética , Isomerismo , Ratones , Unión Proteica , Ratas , Receptores de la Hormona Hipofisaria/metabolismoRESUMEN
Glycogen synthase (GS) catalyzes the transfer of glucose residues from UDP-glucose to a glycogen polymer chain, a critical step for glucose storage. Patients with type 2 diabetes normally exhibit low glycogen levels and decreased muscle glucose uptake is the major defect in whole body glucose disposal. Therefore, activating GS may provide a potential approach for the treatment of type 2 diabetes. In order to identify non-carboxylic acids GS activators, we designed and synthesized a series of 2-N-alkyl- and 2-N-aryl-indazolone derivatives and studied their activity in activating human GS.
Asunto(s)
Diseño de Fármacos , Inhibidores Enzimáticos/farmacología , Glucógeno Sintasa/antagonistas & inhibidores , Indazoles/farmacología , Animales , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/síntesis química , Glucógeno Sintasa/metabolismo , Indazoles/administración & dosificación , Indazoles/síntesis química , Ratones , Ratones Endogámicos C57BL , Estructura Molecular , Relación Estructura-ActividadRESUMEN
A series of non-steroidal GPBAR1 (TGR5) agonists was developed from a hit in a high-throughput screening campaign. Lead identification efforts produced biphenyl-4-carboxylic acid derivative (R)-22, which displayed a robust secretion of PYY after oral administration in a degree that can be correlated with the unbound plasma concentration. Further optimisation work focusing on reduction of the lipophilicity provided the 1-phenylpiperidine-4-carboxylic acid derivative (R)-29 (RO5527239), which showed an improved secretion of PYY and GLP-1, translating into a significant reduction of postprandial blood glucose excursion in an oral glucose tolerance test in DIO mice.
Asunto(s)
Glucemia/efectos de los fármacos , Descubrimiento de Drogas , Oximas/síntesis química , Propano/análogos & derivados , Receptores Acoplados a Proteínas G/agonistas , Administración Oral , Animales , Concentración 50 Inhibidora , Ratones , Estructura Molecular , Oximas/química , Oximas/farmacología , Propano/sangre , Propano/síntesis química , Propano/química , Propano/farmacologíaRESUMEN
BACKGROUND: Atherosclerotic plaque ruptures, triggered by blood flow-associated biomechanical forces, cause most myocardial infarctions and strokes. OBJECTIVES: This study aims to investigate the exact location and underlying mechanisms of atherosclerotic plaque ruptures, identifying therapeutic targets against cardiovascular events. METHODS: Histology, electron microscopy, bulk and spatial RNA sequencing on human carotid plaques were studied in proximal, most stenotic, and distal regions along the longitudinal blood flow direction. Genome-wide association studies were used to examine heritability enrichment and causal relationships of atherosclerosis and stroke. Associations between top differentially expressed genes (DEGs) and preoperative and postoperative cardiovascular events were examined in a validation cohort. RESULTS: In human carotid atherosclerotic plaques, ruptures predominantly occurred in the proximal and most stenotic regions but not in the distal region. Histologic and electron microscopic examination showed that proximal and most stenotic regions exhibited features of plaque vulnerability and thrombosis. RNA sequencing identified DEGs distinguishing the proximal and most stenotic regions from the distal region which were deemed as most relevant to atherosclerosis-associated diseases as shown by heritability enrichment analyses. The identified pathways associated with the proximal rupture-prone regions were validated by spatial transcriptomics, firstly in human atherosclerosis. Of the 3 top DEGs, matrix metallopeptidase 9 emerged particularly because Mendelian randomization suggested that its high circulating levels were causally associated with atherosclerosis risk. CONCLUSIONS: Our findings show plaque site-specific transcriptional signatures associated with proximal rupture-prone regions of carotid atherosclerotic plaques. This led to the geographical mapping of novel therapeutic targets, such as matrix metallopeptidase 9, against plaque rupture.
Asunto(s)
Aterosclerosis , Infarto del Miocardio , Placa Aterosclerótica , Accidente Cerebrovascular , Humanos , Placa Aterosclerótica/patología , Estudio de Asociación del Genoma Completo , Aterosclerosis/complicaciones , Infarto del Miocardio/complicaciones , Accidente Cerebrovascular/complicaciones , MetaloproteasasRESUMEN
Through high throughput screening and subsequent hit identification and optimization, we synthesized a series of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as the first reported potent and reversible GFAT inhibitors. SAR studies of this class of compounds indicated significant impact on GFAT inhibition potency by substitutions on the A-ring and C-ring. The ketone group was found to be necessary for high potency. Compound 28 (RO0509347) demonstrated potent GFAT inhibition (IC(50)=1µM) with a desirable pharmacokinetic profile in rats, and showed significant efficacy in reducing the glucose excursion in an OGTT test in ob/ob mice.
Asunto(s)
Descubrimiento de Drogas , Inhibidores Enzimáticos/farmacología , Glutamina-Fructosa-6-Fosfato Transaminasa (Isomerizadora)/antagonistas & inhibidores , Isoquinolinas/farmacología , Concentración 50 InhibidoraRESUMEN
In a discovery effort to find safe and effective DGAT-1 inhibitors, we have identified 2-phenyloxazole 4-carboxamide 1 as a conformationally constrained analog of a hydrazide hit, which was previously identified from high-throughput screening. Further optimization of this series has led to chemically more stable 2-phenyloxazole-based DGAT-1 inhibitor 25 with improved solubility, cell-based activity, and pharmacokinetic properties. Compound 25 also demonstrated in vivo efficacy in a diet-induced obesity (DIO) rat model.
Asunto(s)
Diacilglicerol O-Acetiltransferasa/antagonistas & inhibidores , Descubrimiento de Drogas , Inhibidores Enzimáticos , Oxazoles/química , Oxazoles/farmacología , Administración Oral , Animales , Peso Corporal , Diacilglicerol O-Acetiltransferasa/química , Modelos Animales de Enfermedad , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Humanos , Concentración 50 Inhibidora , Ratones , Estructura Molecular , Obesidad/tratamiento farmacológico , Oxazoles/uso terapéutico , Ratas , Solubilidad , Relación Estructura-ActividadRESUMEN
BACKGROUND: Tissue fibrosis is the final common phase of chronic allograft injury, the leading cause of late graft loss in kidney transplantation. Preclinical evidence points to the involvement of lysophosphatidic acid (LPA), a bioactive phospholipid, in the development of renal fibrosis. OBJECTIVES: We assessed whether treatment with an orally available inhibitor of autotaxin (ATXi), the main LPA-producing enzyme, could slow the progression of chronic allograft injury in a fully major histocompatibility complex-mismatched rat kidney transplant model and compared its effects with those of the angiotensin-converting enzyme inhibitor lisinopril. METHODS: Kidney allograft recipients were given ciclosporin for the first 15 postoperative days to prevent early acute rejection. Thereafter, they received either no treatment or ATXi or lisinopril and were followed for 180 days after transplantation. RESULTS: Renal LPA levels were increased in allograft rats, providing the rationale for using ATXi in this model. Chronic treatment with ATXi or lisinopril limited progressive proteinuria and ameliorated tubulointerstitial fibrosis compared with allograft rats, although the effects were more robust under ATX inhibition. The administration of ATXi, but not lisinopril, attenuated systemic hypertension, reduced intragraft T cell infiltration, and eventually improved renal graft survival. CONCLUSIONS: In summary, ATXi had protective effects on indices of chronic allograft injury and could be of therapeutic add-on value in the kidney transplant setting. Notably, an ATX inhibitor is currently being investigated in 2 large phase 3 studies in idiopathic pulmonary fibrosis, underscoring the clinical relevance of our findings.
Asunto(s)
Trasplante de Riñón/efectos adversos , Hidrolasas Diéster Fosfóricas/efectos de los fármacos , Trasplante Homólogo/efectos adversos , Animales , Enfermedad Crónica , Rechazo de Injerto , Riñón/metabolismo , Lisofosfolípidos/metabolismo , Masculino , Ratas , Ratas EndogámicasRESUMEN
BACKGROUND AND AIMS: Clinical interventions targeting nonlipid risk factors are needed given the high residual risk of atherothrombotic events despite effective control of dyslipidemia. Dickkopf-1 (DKK1) plays a lipid-independent role in vascular pathophysiology but its involvement in atherosclerosis development and its therapeutic attractiveness remain to be established. METHODS: Patient data, in vitro studies and pharmacological intervention in murine models of atherosclerosis were utilized. RESULTS: In patients' material (n = 127 late stage plaque specimens and n = 10 control vessels), DKK1 mRNA was found to be higher in atherosclerotic plaques versus control arteries. DKK1 protein was detected in the luminal intimal area and in the necrotic core of plaques. DKK1 was released from isolated primary human platelets (~12 - 21-fold) and endothelial cells (~1.4-2.5-fold) upon stimulation with different pathophysiological stimuli. In ApoE-/- and Ldlr-/- mice, plasma DKK1 concentrations were similar to those observed in humans, whereas DKK1 expression in different atheroprone arterial segments was very low/absent. Chronic treatment with a neutralizing DKK1 antibody effectively reduced plasma concentrations, however, plaque lesion area was not reduced in ApoE-/- and Ldlr-/- mice fed a western diet for 14 and 16 weeks. Anti-DKK1 treatment increased bone volume and bone mineral content. CONCLUSIONS: Functional inhibition of DKK1 with an antibody does not alter atherosclerosis progression in classical murine models. This may reflect the absence of DKK1 expression in plaques and more advanced animal disease models could be needed to evaluate the role and therapeutic attractiveness of DKK1 in late stage complications such as plaque destabilization, calcification, rupture and thrombosis.
Asunto(s)
Aterosclerosis , Placa Aterosclerótica , Animales , Anticuerpos Neutralizantes , Aterosclerosis/prevención & control , Modelos Animales de Enfermedad , Células Endoteliales , Humanos , Péptidos y Proteínas de Señalización Intercelular/genética , Ratones , Ratones Endogámicos C57BL , Ratones NoqueadosRESUMEN
This paper describes the lead optimization of a new series of potent, selective, orally bioavailable, brain-penetrant MCH-1 receptor antagonists. A major focus of the work was to achieve a selectivity profile appropriate for in vivo efficacy studies and safety.
Asunto(s)
Indanos/farmacología , Receptores de Somatostatina/antagonistas & inhibidores , Amidas/química , Amidas/farmacocinética , Amidas/farmacología , Animales , Bencimidazoles/química , Bencimidazoles/farmacocinética , Bencimidazoles/farmacología , Cristalografía por Rayos X , Humanos , Indanos/química , Indanos/farmacocinética , Cinética , Piperidinas/química , Piperidinas/farmacocinética , Piperidinas/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de Somatostatina/química , Receptores de Somatostatina/metabolismo , Relación Estructura-ActividadRESUMEN
OBJECTIVE: Type 2 diabetes and obesity are emerging pandemics in the 21st century creating worldwide urgency for the development of novel and safe therapies. We investigated trace amine-associated receptor 1 (TAAR1) as a novel target contributing to the control of glucose homeostasis and body weight. METHODS: We investigated the peripheral human tissue distribution of TAAR1 by immunohistochemistry and tested the effect of a small molecule TAAR1 agonist on insulin secretion in vitro using INS1E cells and human islets and on glucose tolerance in C57Bl6, and db/db mice. Body weight effects were investigated in obese DIO mice. RESULTS: TAAR1 activation by a selective small molecule agonist increased glucose-dependent insulin secretion in INS1E cells and human islets and elevated plasma PYY and GLP-1 levels in mice. In diabetic db/db mice, the TAAR1 agonist normalized glucose excursion during an oral glucose tolerance test. Sub-chronic treatment of diet-induced obese (DIO) mice with the TAAR1 agonist resulted in reduced food intake and body weight. Furthermore insulin sensitivity was improved and plasma triglyceride levels and liver triglyceride content were lower than in controls. CONCLUSIONS: We have identified TAAR1 as a novel integrator of metabolic control, which acts on gastrointestinal and pancreatic islet hormone secretion. Thus TAAR1 qualifies as a novel and promising target for the treatment of type 2 diabetes and obesity.
RESUMEN
We examined the effect of APOC1-317insCGTT allele status (HpaI RFLP, deletion [H1] and insertion [H2] alleles) on serum apolipoprotein (apo) C-I level in 362 Hispanic children in the Columbia University BioMarkers Study. The H2 allele was present in 147 subjects (40.6%). Serum apoC-I was 20% lower in the presence of the H2 allele in APOE epsilon3/epsilon3 homozygotes (P=0.003) but did not differ by H2 status in epsilon4 carriers. Insufficient numbers of epsilon2 carriers (N=45) were present for analysis. In multivariate analysis in the epsilon3/epsilon3 context, after adjusting for potential covariate effects and familial aggregation, the mean effect of H2/* versus H1/H1 on apoC-I level, was estimated to be 2.15+/-0.55mg/dl (P<0.0025). Plasma triglyceride level was weakly correlated with serum apoC-I level (Pearson's r=0.17, P<0.001) but was highly correlated with serum apoC-III (Pearson's r=0.74, P<0.0001). Nevertheless, presence of the H2 allele was not significantly associated with serum apoC-III level. Thus, the effect of APOC1 genotype on serum apoC-I level was not due to apoC-I level serving as a surrogate for triglyceride level. The APOC1-317insCGTT allele is a commonly polymorphic genetic marker that is associated with serum apoC-I level in the APOE epsilon3/epsilon3 context. These findings suggest that the mechanism of the previously described association with plasma TG is, at least in part, related to the correlation of the polymorphism with the level of expression of apoC-I.
Asunto(s)
Apolipoproteínas C/sangre , Apolipoproteínas C/genética , Hispánicos o Latinos , Polimorfismo Genético , Triglicéridos/sangre , Adolescente , Apolipoproteína C-I , Niño , Estudios Transversales , Femenino , Marcadores Genéticos , Genotipo , Humanos , Masculino , Análisis Multivariante , Regiones Promotoras Genéticas/genéticaRESUMEN
We report the discovery of a new monomeric peptide that reduces body weight and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple agonist demonstrates supraphysiological potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors. Such balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis in relevant rodent models. Various loss-of-function models, including genetic knockout, pharmacological blockade and selective chemical knockout, confirmed contributions of each constituent activity in vivo. We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity. These preclinical studies suggest that, so far, this unimolecular, polypharmaceutical strategy has potential to be the most effective pharmacological approach to reversing obesity and related metabolic disorders.
Asunto(s)
Complicaciones de la Diabetes/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Obesidad/metabolismo , Péptidos/administración & dosificación , Animales , Glucemia/efectos de los fármacos , Peso Corporal/genética , Complicaciones de la Diabetes/tratamiento farmacológico , Complicaciones de la Diabetes/genética , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/genética , Péptido 1 Similar al Glucagón/agonistas , Péptido 1 Similar al Glucagón/metabolismo , Células HEK293 , Humanos , Insulina/biosíntesis , Insulina/metabolismo , Ratones , Obesidad/tratamiento farmacológico , Obesidad/genética , Péptidos/síntesis química , Péptidos/metabolismo , Ratas , Receptores de la Hormona Gastrointestinal/agonistas , Receptores de la Hormona Gastrointestinal/metabolismo , Receptores de Glucagón/agonistas , Receptores de Glucagón/metabolismo , RoedoresRESUMEN
We evaluated the influence of sex and hormonal status on the effect of psyllium (PSY) supplementation on parameters of plasma lipoprotein metabolism. Twenty-four men, 23 premenopausal women, and 21 postmenopausal women (PMW) were randomly assigned to a fiber supplement (15 g PSY/d) or a control, provided via cookies, in a crossover design. Plasma lipids, insulin, apoprotein (apo) B, apo CI, apo CIII, and apo E concentrations and the composition and size of low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) particles were measured at the end of each 30-day treatment period. Compared with control, PSY intake decreased plasma LDL cholesterol by an average of 8% (P <.0001) in men and pre- and PMW. There was a fiber-sex/hormonal status interaction on plasma triglycerides (TG) in the response to the intervention. Men had a 17% decrease in TG, while PMW had a 16% increase with PSY (P <.01). Plasma levels of apo C III, apo E, and insulin followed the same pattern as plasma TG with PSY consumption and decreased by an average of 12% in men (P <.05), but increased by 10% in PMW (P <.05). These reductions in apoproteins suggest an increased peripheral removal of TG in men, perhaps due to decreased insulin resistance, while in PMW, the increases in apoproteins may be related to an enhanced VLDL production. The lack of effect of PSY on VLDL metabolism in premenopausal women could be associated with the protective effect of estrogen. No prominent changes in VLDL and LDL composition were observed with PSY intake other than an increase in LDL phospholipid (P <.05). In addition, compared with men and PMW, the amount of TG per VLDL particle was less, and VLDL diameter was smaller in premenopausal women (P <.05). These results indicate an important role of sex and hormonal status in determining the effects of PSY on lipoprotein metabolism.
Asunto(s)
Apolipoproteínas/sangre , Fibras de la Dieta/farmacología , Lipoproteínas/sangre , Posmenopausia , Premenopausia , Psyllium/farmacología , Caracteres Sexuales , Vitamina E/sangre , Análisis de Varianza , Estudios Cruzados , Femenino , Humanos , Insulina/sangre , Lipoproteínas/efectos de los fármacos , Lipoproteínas LDL/sangre , Masculino , Triglicéridos/sangre , alfa-Tocoferol/sangreRESUMEN
A total of 39 postmenopausal women 40-70 years of age and undergoing hormone replacement therapy participated in a 6-month weight reduction program, which consisted of a low calorie diet (5040 KJ/day) and phentermine hydrochloride therapy. Subjects had an average body mass index of 35.95+/-5.32 kg/m(2) and 42.20+/-11.0 kg of total fat. Body mass index, plasma lipids, total and trunk fat, and plasma apoproteins were measured at baseline and after 3 and 6 months of the weight reduction program. Subjects experienced an overall 10% weight loss during the treatment period (P<0.001). Plasma LDL cholesterol and triglycerides were reduced by 18% and 15% (P<0.01) respectively, whereas HDL cholesterol was increased by 9% (P<0.01) over the 6-month period. Plasma apoproteins were significantly affected by weight loss. Plasma apolipoprotein (apo) B concentrations were reduced 6.5% (P<0.01), and apo C-III and apo E were reduced by 9% over 6 months (P<0.01). The observed decreases in plasma apo B were significantly correlated with the observed changes in plasma cholesterol (r=0.356, P<0.01) over 3 months. In addition, changes in plasma triglycerides were correlated with changes in both apo C-III (r=0.436) and apo E (r=0.354) over 6 months. These results suggest that weight loss may have multifactorial effects on lipoprotein metabolism, resulting in better plasma lipid and apoprotein profiles.
Asunto(s)
Apolipoproteínas/sangre , Posmenopausia/sangre , Pérdida de Peso , Adulto , Anciano , Apolipoproteína C-III , Apolipoproteínas B/sangre , Apolipoproteínas C/sangre , Apolipoproteínas E/sangre , Depresores del Apetito/uso terapéutico , Índice de Masa Corporal , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Dieta Reductora , Ingestión de Energía , Terapia de Reemplazo de Estrógeno , Femenino , Humanos , Persona de Mediana Edad , Fentermina/uso terapéutico , Triglicéridos/sangreRESUMEN
The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor ß (THR-ß) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor α (THR-α). A pyridazinone series has been identified that is significantly more THR-ß selective than earlier analogues. Optimization of this series by the addition of a cyanoazauracil substituent improved both the potency and selectivity and led to MGL-3196 (53), which is 28-fold selective for THR-ß over THR-α in a functional assay. Compound 53 showed outstanding safety in a rat heart model and was efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. In reported studies in healthy volunteers, 53 exhibited an excellent safety profile and decreased LDL cholesterol (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.
Asunto(s)
Descubrimiento de Drogas , Dislipidemias/tratamiento farmacológico , Piridazinas/síntesis química , Receptores beta de Hormona Tiroidea/agonistas , Uracilo/análogos & derivados , Animales , Densidad Ósea/efectos de los fármacos , Ensayos Clínicos como Asunto , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Piridazinas/metabolismo , Piridazinas/farmacología , Piridazinas/uso terapéutico , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Uracilo/síntesis química , Uracilo/metabolismo , Uracilo/farmacología , Uracilo/uso terapéuticoRESUMEN
We applied noncovalent complexes of digoxigenin (Dig) binding antibodies with digoxigeninylated peptide derivatives to modulate their pharmacokinetic properties. A peptide derivative which activates the Y2R receptor was selectively mono-digoxigeninylated by reacting a NHS-Dig derivative with an ε-amino group of lysine 2. This position tolerates modifications without destroying receptor binding and functionality of the peptide. Dig-peptide derivatives can be loaded onto Dig-binding IgGs in a simple and robust reaction, thereby generating peptide-IgG complexes in a defined two to one molar ratio. This indicates that each antibody arm becomes occupied by one haptenylated peptide. In vitro receptor binding and signaling assays showed that Dig-peptides as well as the peptide-antibody complexes retain better potency than the corresponding pegylated peptides. In vivo analyses revealed prolonged serum half-life of antibody-complexed peptides compared to unmodified peptides. Thus, complexes are of sufficient stability for PK modulation. We observed more prolonged weight reduction in a murine diet-induced obesity (DIO) model with antibody-complexed peptides compared to unmodified peptides. We conclude that antibody-hapten complexation can be applied to modulate the PK of haptenylated peptides and in consequence improve the therapeutic efficacy of therapeutic peptides.